A$0.15 0.0 3.5%
Last Trade - 2:44am
| Market Cap | £260.9m |
| Enterprise Value | £248.4m |
| Revenue | £34.9k |
| Position in Universe | 428th / 1838 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.81 | 0.000 | 2.76 | 0.048 | 0.000 | 0.063 | -40.1% | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
PYC Therapeutics Limited, formerly Phylogica Limited, is a pharmaceutical company. The Company is engaged combining its cell-penetrating peptides (CPP) technology with in ASOs to create a pipeline of drugs called CPP-ASOs. The Company intends to expand its pipeline to include other disease indications and therapeutic areas such as genetic neurodegenerative and liver diseases. Its pipeline products is Ocular, which is focused on treating retinitis pigmentosa and inherited retinal disease.
| Last Annual | June 30th, 2020 |
| Last Interim | June 30th, 2020 |
| Incorporated | October 9, 2001 |
| Public Since | March 30, 2005 |
| No. of Shareholders: | n/a |
| No. of Employees: | 23 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | S&P/ASX All Ordinaries , |
| Exchange | Australian Stock Exchange - SEATS |
| Shares in Issue | 3,224,735,790 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Harry Perkins Institute 6 Verdun St, NEDLANDS, 6009, Australia |
| Web | https://pyctx.com/ |
| Phone | +61 8 61510992 |
| Contact | Rudi Michelson (IR Contact Officer) |
| Auditors | HLB Mann Judd |
As of 2:44am, shares in PYC Therapeutics are trading at A$0.15, giving the company a market capitalisation of £260.9m. This share price information is delayed by 15 minutes.
Shares in PYC Therapeutics are currently trading at A$0.15 and the price has moved by 0.148k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the PYC Therapeutics price has moved by 0.128k% over the past year.
Of the analysts with advisory recommendations for PYC Therapeutics, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for PYC Therapeutics is Not available. You can view the full broker recommendation list by unlocking its StockReport.
PYC Therapeutics is scheduled to issue upcoming financial results on the following dates:
PYC Therapeutics does not currently pay a dividend.
PYC Therapeutics does not currently pay a dividend.
PYC Therapeutics does not currently pay a dividend.
To buy shares in PYC Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in PYC Therapeutics are currently trading at A$0.15, giving the company a market capitalisation of £260.9m.
Here are the trading details for PYC Therapeutics:
Based on an overall assessment of its quality, value and momentum, PYC Therapeutics is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We were not able to load any forecast data for PYC Therapeutics.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PYC Therapeutics. Over the past six months, the relative strength of its shares against the market has been 14.18%. At the current price of A$0.15, shares in PYC Therapeutics are trading at 7.13% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for PYC Therapeutics.
PYC Therapeutics's management team is headed by:
Here are the top five shareholders of PYC Therapeutics based on the size of their shareholding:
